DaVita SG&A Expenses 2010-2024 | DVA

DaVita sg&a expenses for the twelve months ending June 30, 2024 were $1.509B, a 4.71% increase year-over-year.

  • DaVita annual sg&a expenses for 2023 were $1.474B, a 8.77% increase from 2022.
  • DaVita annual sg&a expenses for 2022 were $1.355B, a 13.37% increase from 2021.
  • DaVita annual sg&a expenses for 2021 were $1.195B, a 4.19% decline from 2020.

DaVita SG&A Expenses 2010-2024 | DVA

  • DaVita annual sg&a expenses for 2023 were $1.474B, a 8.77% increase from 2022.
  • DaVita annual sg&a expenses for 2022 were $1.355B, a 13.37% increase from 2021.
  • DaVita annual sg&a expenses for 2021 were $1.195B, a 4.19% decline from 2020.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$21.4B
Quest Diagnostics (DGX)$17.3B
Encompass Health (EHC)$9.2B
Chemed (CHE)$8.7B
Elanco Animal Health (ELAN)$7.1B
Option Care Health (OPCH)$5.3B
RadNet (RDNT)$4.9B
Amedisys (AMED)$3.2B
Astrana Health (ASTH)$2.7B
LifeStance Health (LFST)$2.6B
Addus HomeCare (ADUS)$2.4B
U.S Physical Therapy (USPH)$1.3B
Pennant (PNTG)$1B
Aveanna Healthcare Holdings (AVAH)$1B
Atai Life Sciences (ATAI)$215M
Daxor (DXR)$46M
ATI Physical Therapy (ATIP)$26M
MEDIROM Healthcare Technologies (MRM)$19M
Psychemedics (PMD)$14M
Ontrak (OTRK)$10M
Novo Integrated Sciences (NVOS)$5M
IMAC Holdings (BACK)$2M